These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31031030)

  • 1. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
    Cohet C; van der Most R; Bauchau V; Bekkat-Berkani R; Doherty TM; Schuind A; Tavares Da Silva F; Rappuoli R; Garçon N; Innis BL
    Vaccine; 2019 May; 37(23):3006-3021. PubMed ID: 31031030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
    Ahmed SS; Schur PH; MacDonald NE; Steinman L
    J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
    Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
    Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
    Andrews NJ; Walker WT; Finn A; Heath PT; Collinson AC; Pollard AJ; Snape MD; Faust SN; Waight PA; Hoschler K; Sheasby L; Waddington C; Kerridge S; Chalk J; Reiner A; John T; Fletcher M; Allen R; Fineman N; Wilkins S; Casey M; Michaelis L; Oeser C; Okike I; Ladhani S; Miller E
    Vaccine; 2011 Oct; 29(45):7913-9. PubMed ID: 21875635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
    Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM
    Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
    Vaughn DW; Seifert H; Hepburn A; Dewe W; Li P; Drame M; Cohet C; Innis BL; Fries LF
    Hum Vaccin Immunother; 2014; 10(10):2942-57. PubMed ID: 25483467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
    Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
    Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults.
    Rostad CA; Atmar RL; Walter EB; Frey S; Meier JL; Sherman AC; Lai L; Tsong R; Kao CM; Raabe V; El Sahly HM; Keitel WA; Whitaker JA; Smith MJ; Schmader KE; Swamy GK; Abate G; Winokur P; Buchanan W; Cross K; Wegel A; Xu Y; Yildirim I; Kamidani S; Rouphael N; Roberts PC; Mulligan MJ; Anderson EJ
    Clin Infect Dis; 2024 Jun; 78(6):1757-1768. PubMed ID: 38537255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
    Langley JM; Frenette L; Chu L; McNeil S; Halperin S; Li P; Vaughn D
    BMC Infect Dis; 2012 Oct; 12():279. PubMed ID: 23110320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
    Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
    J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
    Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
    Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
    Madan A; Ferguson M; Sheldon E; Segall N; Chu L; Toma A; Rheault P; Friel D; Soni J; Li P; Innis BL; Schuind A
    Vaccine; 2017 Mar; 35(10):1431-1439. PubMed ID: 28187952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
    Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
    JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
    Walker WT; Faust SN
    Expert Rev Vaccines; 2010 Dec; 9(12):1385-98. PubMed ID: 21105775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.
    Vesikari T; Richardus JH; Berglund J; Korhonen T; Flodmark CE; Lindstrand A; Silfverdal SA; Bambure V; Caplanusi A; Dieussaert I; Roy-Ghanta S; Vaughn DW
    Pediatr Infect Dis J; 2015 Jul; 34(7):774-82. PubMed ID: 26069949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
    Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
    Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.